Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from ...

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...

GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials March 03, 2025 — 02:45 am EST Written by RTTNews.com for RTTNews -> ...

Home News GlobeNewswire Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First ...

Although patients with asthma commonly have coexisting chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP), research on the effect of biologics has focused on ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo ...

The FDA has accepted for priority review the supplemental biologics license application of dupilumab for adolescents with chronic rhinosinusitis with nasal polyps, Regeneron Pharmaceuticals Inc ...

The sBLA for adolescents is supported by an extrapolation of efficacy data from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis (EoE ...